23andMe Holding Co. - Common Stock (ME)
0.7700
+0.2395 (45.15%)
23andMe Holding Co. is a biotechnology company that specializes in personal genomics and biotechnology research
It offers direct-to-consumer genetic testing services, allowing individuals to explore their ancestry, health risks, and genetic traits through easy-to-use saliva collection kits. The company aims to empower people with insights into their genetic information and provide valuable resources for health-related decision-making. Additionally, 23andMe is involved in pharmaceutical research, leveraging its vast genetic database to facilitate drug discovery and development through collaborations with various biopharmaceutical companies.
Previous Close | 0.5305 |
---|---|
Open | 0.6025 |
Bid | 0.7108 |
Ask | 0.7363 |
Day's Range | 0.5936 - 1.370 |
52 Week Range | 0.5300 - 12.76 |
Volume | 179,451,497 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 8,755,639 |
News & Press Releases
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · March 27, 2025
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via Chartmill · March 27, 2025
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · March 27, 2025
Via Benzinga · March 27, 2025
Receives Court Approval for First Day Motions to Support Ongoing Business Operations
By 23andMe, Inc. · Via GlobeNewswire · March 26, 2025
Cybersecurity is "the one line item that no company in the world is cutting," Brown said, noting how a data breach brought down 23andMe.
Via Benzinga · March 26, 2025
23andMe files for Chapter 11 bankruptcy, raising concerns about genetic data security as legal challenges emerge over a $30 million data breach settlement.
Via Benzinga · March 25, 2025
U.S. stock futures declined on Tuesday, after advancing for two consecutive sessions on Friday and Monday.
Via Benzinga · March 25, 2025
The S&P 500 and Nasdaq posted their best gains in months, with the S&P 500 climbing 1.76% to 5,767.57 and the Nasdaq rising 2.3% to 18,188.59.
Via Benzinga · March 24, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · March 24, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · March 24, 2025
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
Via Chartmill · March 24, 2025
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · March 24, 2025
Via Benzinga · March 24, 2025
Shares of 23andMe are falling in premarket trading after the company filed for Chapter 11 bankruptcy to initiate a court-supervised sale process aimed at maximizing business value.
Via Benzinga · March 24, 2025
Via Benzinga · March 24, 2025
Stock futures rise on bullish sentiment as Trump administration plans targeted tariffs against trading partners.
Via Benzinga · March 24, 2025
Via Benzinga · March 24, 2025
Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities
By 23andMe, Inc. · Via GlobeNewswire · March 23, 2025
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels
By 23andMe, Inc. · Via GlobeNewswire · March 21, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · March 3, 2025

SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a non-binding proposal from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of capital stock of 23andMe not owned by Ms. Wojcicki and her affiliates (or any other stockholders that she invites to “roll over” their current equity ownership) for cash consideration of $0.41 per share. Ms. Wojcicki’s proposal, which was included in an amended Schedule 13D filing made by Ms. Wojcicki with the Securities and Exchange Commission earlier today, represented an 84% decrease to the $2.53 per share price included in the joint non-binding proposal previously submitted by Ms. Wojcicki and her then co-bidder on February 20, 2025.
By 23andMe, Inc. · Via GlobeNewswire · March 3, 2025

Tariffs on metal imports create opportunities in ETFs focused on U.S. steelmakers. Top picks are VanEck Steel, SPDR S&P Metals & Mining, and Global X U.S. Infrastructure Development ETF.
Via Benzinga · February 12, 2025